Effect of Foretinib on Matrix Metalloproteinase-2 (MMP2) Expression in Glioblastoma

Background: The most malignant form of infiltrating astrocytoma, glioblastoma multiforme (GBM), is one of the most aggressive human cancers. Foretinib diminished GBM cell invasion by downregulating the expression of matrix metalloproteinase 2 (MMP2). The study aimed to examine the anti-tumor activity of foretinib and to test its effect on MMP2 expression in T98 cells. Materials and Methods: T98 cells were used as an experimental model of glioblastoma. The effect of foretinib on the expression of MMP2 was evaluated using quantitative real-time polymerase chain reaction. Thereafter, the effect of foretinib on the enzyme levels of MMP was examined by zymography. Statistical analyses were performed with GraphPad Prism software. Results: A reduction in the expression of MMP2 was observed with an increase in the concentration of foretinib. Conclusion: Foretinib treatment leads to downregulation of MMP-2 and has a positive effect on T98 cells. We believe that foretinib can be subjected to further clinical investigation to develop a treatment for GBM.